PYC Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYC.AX research report →
Price Chart
About the company
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.
- CEO
- Rohan Hockings
- IPO
- 2024
- Employees
- 37
- HQ
- Nedlands, WA, AU
Get TickerSpark's AI analysis on PYC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.21B
- P/E
- -24.50
- Fwd P/E
- 26.32
- PEG
- 0.13
- P/S
- 103.53
- P/B
- 8.40
- EV/EBITDA
- -18.18
- Div Yield
- 0.00%
- Gross Margin
- 97.40%
- Op Margin
- -519.52%
- Net Margin
- -407.99%
- ROE
- -30.03%
- ROIC
- -26.11%
Latest fiscal year · YoY change
- Revenue
- $23.49M+6.5%
- Gross Profit
- $23.49M+6.5%
- Op Income
- $-53,627,837
- Net Income
- $-50,304,679-33.3%
- EPS
- $-0.10-941.7%
- OCF Growth
- -33.6%
- FCF Growth
- -35.1%
- 52W High
- $2.23
- 52W Low
- $0.85
- 50D MA
- $1.73
- 200D MA
- $1.49
- Beta
- 1.05
- RSI (14)
- 60
- Avg Volume
- 1.73M
No earnings-call transcripts are available for PYC.AX yet.
- Free Float
- 35.7%
- Shares Outstanding
- 583.05M
- Float Shares
- 208.20M
Held by 47 ETFs
Biggest fund positions in PYC.AX by dollar value.
Our PYC.AX coverage
Recent articles, reports, and earnings notes.
No research on PYC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PYC.AX report →